2ND LINE HORMONAL-THERAPY WITH AMINOGLUTETHIMIDE IN METASTATIC BREAST-CANCER

被引：10

作者：

BRUFMAN, G

BIRAN, S

机构：

[1] Department of Clinical Oncology, Hadassah University Hospital, Jerusalem

来源：

ACTA ONCOLOGICA | 1990年 / 29卷 / 06期

关键词：

Aminoglutethimide; Breast cancer; Tamoxifen;

D O I：

10.3109/02841869009092989

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

One hundred and twenty patients with metastatic breast cancer, whose disease progressed on hormonal therapy with tamoxifen, were treated with aminoglutethimide. The overall response rate was 34% and the median duration of response 9.5 months. Response to aminoglutethimide was achieved in all metastatic sites except lung and brain. Even 25% of patients who had failed to respond to prior tamoxifen did respond objectively to aminoglutethimide. The actuarial survival for all patients at 30 months was 22% Although initial toxicity was high (70% side effects of aminoglutethimide were transient, and treatment had to be discontinued in only four patients. The results of this trial confirm that aminoglutethimide is an effective treatment in metastatic breast cancer. ©1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

收藏

页码：717 / 720

页数：4

相关论文

共 50 条

[31] SEROLOGICAL MARKERS FOR METASTATIC BREAST-CANCER [J].

NG, JSY ;

STURGEON, CM ;

SETH, J ;

PATERSON, GM ;

ROULSTON, JE ;

LEONARD, RCF .

DISEASE MARKERS, 1993, 11 (5-6) :217-223

[32] Sequential Hormonal Therapy for Metastatic Breast Cancer after Adjuvant Tamoxifen or Anastrozole [J].

Robert W. Carlson ;

I. Craig Henderson .

Breast Cancer Research and Treatment, 2003, 80 (Suppl 1) :19-26

[33] Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients [J].

Carlini, Paolo ;

Michelotti, Andrea ;

Ferretti, Gianluigi ;

Ricci, Sergio ;

Giannarelli, Diana ;

Biostatistic, Diana Giannarelli ;

Pellegrini, Manuela ;

Cresti, Nicola ;

Di Cosimo, Serena ;

Bria, Emilio ;

Papaldo, Paola ;

Fabi, Alessandra ;

Ruggeri, Enzo Maria ;

Milella, Michele ;

Alimonti, Andrea ;

Salesi, Nello ;

Cognetti, Francesco .

CANCER INVESTIGATION, 2007, 25 (02) :102-105

[34] THE EBCTCG OVERVIEW OF ADJUVANT THERAPY OF BREAST-CANCER [J].

GRAY, R ;

CLARKE, M .

PATHOLOGIE BIOLOGIE, 1994, 42 (01) :36-36

[35] HOW TO IMPROVE ENDOCRINE THERAPY OF BREAST-CANCER [J].

KVINNSLAND, S .

ACTA ONCOLOGICA, 1990, 29 (03) :387-389

[36] ADJUVANT THERAPY OF BREAST-CANCER [J].

GOLDHIRSCH, A ;

GELBER, RD ;

CASTIGLIONE, M .

EUROPEAN JOURNAL OF CANCER, 1991, 27 (03) :389-399

[37] INFLUENCE OF AMINOGLUTETHIMIDE ON PLASMA ESTROGEN-LEVELS IN BREAST-CANCER PATIENTS ON 4-HYDROXYANDROSTENEDIONE TREATMENT [J].

LONNING, PE ;

DOWSETT, M ;

JONES, A ;

EKSE, D ;

JACOBS, S ;

MCNEIL, F ;

JOHANNESSEN, DC ;

POWLES, TJ .

BREAST CANCER RESEARCH AND TREATMENT, 1992, 23 (1-2) :57-62

[38] HER2-positive metastatic Breast Trastuzumab Emtansine: New Standard for the 2nd-line-Therapy [J].

Satzger, Ulla .

ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (11)

[39] Hormonal therapy for postmenopausal breast cancer: the science of sequencing [J].

Miller, William R. ;

Bartlett, John M. S. ;

Canney, Peter ;

Verrill, Mark .

BREAST CANCER RESEARCH AND TREATMENT, 2007, 103 (02) :149-160

[40] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients [J].

Jacquet, E. ;

Lardy-Cleaud, A. ;

Pistilli, B. ;

Franck, S. ;

Cottu, P. ;

Delaloge, S. ;

Debled, M. ;

Vanlemmens, L. ;

Leheurteur, M. ;

Guizard, A. V. ;

Laborde, L. ;

Uwer, L. ;

Jacot, W. ;

Berchery, D. ;

Desmoulins, I. ;

Ferrero, J. M. ;

Perrocheau, G. ;

Courtinard, C. ;

Brain, E. ;

Chabaud, S. ;

Robain, M. ;

Bachelot, T. .

EUROPEAN JOURNAL OF CANCER, 2018, 95 :93-101

← 1 2 3 4 5 →